Doctor Heike Schwende
Novartis Pharma AG, Basel (Switzerland)
Comparative effectiveness of sacubitril/valsartan versus angiotensin converting enzyme inhibitors/angiotensin receptor blockers in de novo heart failure patients
Event: ESC Congress 2022
Topic: Pharmacotherapy
Session: Heart failure pharmacotherapy - Sacubitril/valsartan
ESC 365 is supported by
